Wanbury has received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade. This is the third consecutive approval from ANVISA to Wanbury’s APIs enabling customer to use its APIs for formulations.
The company is committed to meet customer demands & strive for quality excellence. The company has initiated talks with various customers to increase the volume of business from its customers.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.